Literature DB >> 28634076

lncRNA HULC promotes the growth of hepatocellular carcinoma cells via stabilizing COX-2 protein.

Haojun Xiong1, Bo Li1, Jintao He2, Yijun Zeng1, Yan Zhang3, Fengtian He4.   

Abstract

Highly upregulated in liver cancer (HULC), a lncRNA overexpressed in hepatocellular carcinoma (HCC), has been demonstrated to be involved in the carcinogenesis and progression of HCC. However, the mechanisms of HULC promoting the abnormal growth of HCC cells are still not well elucidated. In the present study, we for the first time demonstrated that HULC promoted the growth of HCC cells through elevating COX-2 protein. Moreover, the study of the corresponding mechanism by which HULC upregulated COX-2 showed that HULC enhanced the level of ubiquitin-specific peptidase 22 (USP22), which decreased ubiquitin-mediated degradation of COX-2 protein by removing the conjugated polyubiquitin chains from COX-2 and finally stabilized COX2 protein. In addition, knockdown of USP22 or COX-2 attenuated HULC-mediated abnormal growth of HCC cells. In conclusion, our results demonstrated that "USP22/COX-2" axis played an important role in HULC promoting growth of HCC cells. The identification of this novel pathway may pave a road for developing new potential anti-HCC strategies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COX-2; HCC; HULC; Tumor growth; USP22

Mesh:

Substances:

Year:  2017        PMID: 28634076     DOI: 10.1016/j.bbrc.2017.06.103

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Down-regulation of LncRNA UCA1 alleviates liver injury in rats with liver cirrhosis.

Authors:  Yinhong Zhu; Xiaobei Chen; Chunhua Zheng; Xianlin Rao; Xiaomou Peng
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

Review 2.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

3.  Inhibition of lncRNA RET enhances radio-sensitivity of tumor cells via miR-3179/Slug/PTEN axis.

Authors:  Xinxin Liang; Xueping Li; Ping Wang; Zhongmin Chen; Ziyan Yan; Xingkun Ao; Yuhao Liu; Jiaojiao Zhu; Tingting Xi; Shenghui Zhou; Zhongqiu Li; Chao Li; Maoxiang Zhu; Ping-Kun Zhou; Yongqing Gu
Journal:  Toxicol Res (Camb)       Date:  2022-04-01       Impact factor: 2.680

4.  Lantern: an integrative repository of functional annotations for lncRNAs in the human genome.

Authors:  Swapna Vidhur Daulatabad; Rajneesh Srivastava; Sarath Chandra Janga
Journal:  BMC Bioinformatics       Date:  2021-05-26       Impact factor: 3.169

Review 5.  Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis.

Authors:  Aya El Khodiry; Menna Afify; Hend M El Tayebi
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

Review 6.  The Role of Long Non-Coding RNAs in Hepatocarcinogenesis.

Authors:  Manuela Lanzafame; Gaia Bianco; Luigi M Terracciano; Charlotte K Y Ng; Salvatore Piscuoglio
Journal:  Int J Mol Sci       Date:  2018-02-28       Impact factor: 5.923

Review 7.  Implications of Long Non-Coding RNAs in Age-Altered Proteostasis.

Authors:  Cristina-Sorina Catana; Catalina-Angela Crișan; Dana Opre; Ioana Berindan-Neagoe
Journal:  Aging Dis       Date:  2020-05-09       Impact factor: 6.745

8.  Quantitative proteomics analysis of glioblastoma cell lines after lncRNA HULC silencing.

Authors:  Shan Ye; Jing Wu; Yiran Wang; Yuchen Hu; Tiantian Yin; Jie He
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

Review 9.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083

10.  Long noncoding RNA highly upregulated in liver cancer promotes the progression of hepatocellular carcinoma and attenuates the chemosensitivity of oxaliplatin by regulating miR-383-5p/vesicle-associated membrane protein-2 axis.

Authors:  Peng Li; Yuwei Li; Lieting Ma
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.